MoneyWorks4Me

Jenburkt Pharmaceuticals planning to launch Favipiravir-200 mg tablets

21 Jul 2020 Evaluate

Jenburkt Pharmaceuticals has planned to launch Favipiravir-200 mg tablets, recommended for the treatment of mild to moderate COVID-19 patients.

Jenburkt Pharmaceuticals is engaged in manufacturing and marketing of speciality and high quality pharmaceutical formulations and healthcare products.

Peers
Company Name CMP
Sun Pharma. Inds. 1745.00
Dr. Reddys Labs. 1237.65
Cipla 1313.80
Lupin 1957.00
Zydus Lifesciences 1117.30
View more..